Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 1
Submit an article Journal homepage
1,320
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Determining the cost–effectiveness of adult pneumococcal vaccination strategies

Kenneth J SmithUniversity of Pittsburgh, 200 Meyran Ave, Suite 200, Pittsburgh, PA 15213, USACorrespondence[email protected]
Pages 1-4 | Published online: 16 Dec 2013

References

  • Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal Wkly Rep. 61, 816–819 (2012).
  • Smith KJ, Zimmerman RK, Lin CJ et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 26(11), 1420–1431 (2008).
  • Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 307(8), 804–812(2012).
  • Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb. Mortal Wkly Rep. 59(34), 1102–1106 (2010).
  • French N, Gordon SB, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med. 362(9), 812–822 (2010).
  • Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32–41 (2010).
  • Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin. Infect. Dis. 55(2), 265–267 (2012).
  • Cohen AL, Harrison LH, Farley MM et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 24(14), 2253–2262 (2010).
  • Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25(6), 494–501 (2006).
  • Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med. 138(12), 960–968 (2003).
  • Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 21(3–4), 303–311 (2002).
  • Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010–2020. Vaccine 31(22), 2572–2577 (2013).
  • Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 28(12), 2367–2369 (2010).
  • Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am. J. Prev. Med. 44(4), 373–381 (2013).
  • Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med. Care 36(1), 8–27 (1998).
  • Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 345, e6879 (2012).
  • Smith KJ, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine 31(37), 3950–3956 (2013).
  • Kaplan SL, Barson WJ, Lin PL et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 32(3), 203–207 (2013).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.